As a word of caution, small-molecule TRPV1 antagonists were effective analgesic agents in animal models of inflammatory and neuropathic pain, yet, they failed in clinical trials to relieve migraine or osteoarthritis pain [160,161]. This evidence concerns the gene TRPV1 and migraine disorder.